Lamellar Biomedical Company Culture

Lamellar Biomedical Company Overview

Developer of novel healthcare products based on the mimicry or modification of the lamellar body secretory system designed to treat Dry Eye Disease, RIX, Cystic Fibrosis and Infection. The company's LAMELLASOME technology produces mimetics of human serous lamellar bodies, these regulate the internal interfaces between human tissues as well as the interfaces between tissues and the external environment as in the mouth and lungs. They act biophysically are muco-restorative and have the potential to resolve a broad range of disease states that are associated with dry or sticky mucosal surfaces and topical infection, such as CF treating therapeutic needs of patients with certain ophthalmic, respiratory, cardiovascular, immunological, dermatological, conditions as well bacterially caused infectious diseases and conditions in the supportive care arena resulting from radiation based therapy for cancer.

Lamellar Biomedical was founded in 2007 and its current CEO is Alec McLean. Since its inception 19 years ago, Lamellar Biomedical has grown to 10 employees.